MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
MedinCell (Paris:MEDCL) will hold an audio conference for its shareholders as well as the financial community on Tuesday, June 4, to present the results for the 2018-2019 financial year which ended on March 31, 2019:
- 6.30 pm CEST – Presentation and Q&A in French
- 7.30 pm CEST – Presentation and Q&A in English
- Link to connect: invest.medincell.com/conference
An internet connection will be required to access the conference and ask questions.
The annual financial report will be available on the MedinCell website, in the Investors section (invest.medincell.com), as well as on the website of the Autorité des Marchés Financiers (AMF).
For reasons related to its management agenda, MedinCell informs its shareholders that its Annual General Meeting will finally be held on Thursday, September 5, 2019 in Montpellier.
MedinCell is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.